Advertisement

A Randomised Trial of Two Radiotherapy Schedules in the Adjuvant Treatment of Stage I Seminoma (MRC TE18) — Preliminary Report

  • W. G. Jones
  • S. D. Fossa
  • G. M. Mead
  • J. T. Roberts
  • M. Sokal
  • S. Naylor
  • S. P. Stenning
  • MRC Testicular Tumour Working Party

Abstract

Adjuvant post-orchidectomy radiotherapy cures the majority of patients with stage I seminoma, but as approximately 80 per cent would remain relapse-free on surveillance alone, minimising radiotherapy — and hence morbidity and second cancer risk — is a worthwhile aim. An earlier MRC trial (TE10) assessed the impact of reducing radiotherapy field size from the dog-leg field to the para-aortic strip only. This follow-on trial assessed the impact of reducing radiotherapy dose on relapse rates, acute morbidity and quality of life.

Keywords

Relapse Rate Reduce Radiotherapy Dose Diary Card Clinical Trial Unit Symptom Diary 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer-Verlag London Limited 2002

Authors and Affiliations

  • W. G. Jones
    • 1
  • S. D. Fossa
    • 1
  • G. M. Mead
    • 1
  • J. T. Roberts
    • 1
  • M. Sokal
    • 1
  • S. Naylor
    • 1
  • S. P. Stenning
    • 1
  • MRC Testicular Tumour Working Party
    • 1
  1. 1.MRC Clinical Trials UnitLondonUK

Personalised recommendations